FDA Grants Orphan Drug Designation to HUTCHMED’s Sovleplenib
The FDA granted orphan drug designation to HUTCHMED’s sovleplenib for autoimmune hemolytic anemia.
Related stories
South Korea Proposes Delaying Crypto Gains Tax Until 2029
The government backed another two-year postponement, which would mark the fourth delay. Finance Minister Lee Hyoung-il said lawmakers would be consulted on the proposal.
L impact | REGULATION | Nov 05, 2026, 09:41 AM UTC
China to Keep Anti-Dumping, Anti-Subsidy Tariffs on US n-Propanol for Five Years
China will maintain anti-dumping and anti-subsidy tariffs on imports of n-Propanol from the US for five more years.
L impact | REGULATION | Nov 05, 2026, 09:36 AM UTC
Court Rejects Injunction Blocking Cellid Share Issuance
The Seoul Central District Court rejected an injunction seeking to block Cellid's new share issuance.
M impact | REGULATION | Nov 05, 2026, 09:35 AM UTC
Japan Finance Ministry Warns Against Funding Defense Buildup With New Debt
Japan’s finance ministry warned against financing the country’s defense buildup with new debt.
L impact | REGULATION | Nov 05, 2026, 09:27 AM UTC
Russia to Increase Forex Purchases in November
Russia says it will increase foreign-exchange purchases in November.
L impact | REGULATION | Nov 05, 2026, 09:12 AM UTC
China to Continue Anti-Subsidy Duties on US NPA Imports for Five Years
China's commerce ministry said it will continue imposing anti-subsidy duties on US NPA imports for five years.
L impact | REGULATION | Nov 05, 2026, 09:10 AM UTC